Apeloa PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Apeloa PharmaceuticalLtd de 16.6% y 10.7% por año respectivamente. Se prevé que el BPA crezca en un 16.4% al año. Se espera que la rentabilidad financiera sea de 17.3% en 3 años.

Información clave

16.6%

Tasa de crecimiento de los beneficios

16.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.7%
Tasa de crecimiento de los ingresos	10.7%
Rentabilidad financiera futura	17.3%
Cobertura de analistas	Low
Última actualización	25 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) Looks Inexpensive But Perhaps Not Attractive Enough

Nov 09

Apeloa PharmaceuticalLtd (SZSE:000739) Seems To Use Debt Quite Sensibly

Sep 30

Lacklustre Performance Is Driving Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Low P/E

Aug 07

Is Apeloa PharmaceuticalLtd (SZSE:000739) Using Too Much Debt?

Jun 24

Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

May 08

Previsiones de crecimiento de beneficios e ingresos

SZSE:000739 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	15,554	1,561	1,713	1,809	4
12/31/2025	14,247	1,338	1,459	1,648	5
12/31/2024	12,718	1,144	77	1,679	5
9/30/2024	12,264	1,074	764	1,349	N/A
6/30/2024	11,948	1,079	636	1,270	N/A
3/31/2024	11,587	1,060	454	1,089	N/A
12/31/2023	11,474	1,055	401	1,031	N/A
9/30/2023	11,494	1,183	784	1,304	N/A
6/30/2023	11,514	1,153	1,383	1,740	N/A
3/31/2023	11,529	1,076	899	1,377	N/A
1/1/2023	10,545	989	817	1,326	N/A
9/30/2022	10,094	851	326	822	N/A
6/30/2022	9,651	839	-140	617	N/A
3/31/2022	9,077	890	-160	635	N/A
1/1/2022	8,943	956	-90	612	N/A
9/30/2021	8,468	949	-35	722	N/A
6/30/2021	8,165	941	180	738	N/A
3/31/2021	8,146	879	675	1,048	N/A
12/31/2020	7,880	817	742	1,060	N/A
9/30/2020	7,606	752	1,156	1,276	N/A
6/30/2020	7,653	702	1,419	1,471	N/A
3/31/2020	7,236	598	1,282	1,340	N/A
12/31/2019	7,211	553	1,328	1,360	N/A
9/30/2019	7,122	529	1,258	1,316	N/A
6/30/2019	6,855	465	966	1,029	N/A
3/31/2019	6,605	414	714	811	N/A
12/31/2018	6,376	371	751	833	N/A
9/30/2018	6,246	367	433	523	N/A
6/30/2018	5,882	313	N/A	425	N/A
3/31/2018	5,674	275	N/A	410	N/A
12/31/2017	5,552	257	N/A	210	N/A
9/30/2017	5,313	253	N/A	465	N/A
6/30/2017	5,312	279	N/A	307	N/A
3/31/2017	5,112	274	N/A	304	N/A
12/31/2016	4,772	263	N/A	180	N/A
9/30/2016	4,476	201	N/A	223	N/A
6/30/2016	4,349	190	N/A	304	N/A
3/31/2016	4,284	198	N/A	255	N/A
12/31/2015	4,338	208	N/A	441	N/A
9/30/2015	4,195	231	N/A	580	N/A
6/30/2015	4,219	236	N/A	642	N/A
3/31/2015	4,281	241	N/A	750	N/A
12/31/2014	4,233	322	N/A	787	N/A
9/30/2014	4,112	313	N/A	435	N/A
6/30/2014	4,100	305	N/A	391	N/A
3/31/2014	3,991	274	N/A	198	N/A
12/31/2013	3,855	167	N/A	190	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (16.6% al año) de 000739 es superior a la tasa de ahorro (2.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (16.6% al año) de 000739 crezcan menos que el mercado CN (26.1% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 000739 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (10.7% al año) de 000739 crezcan más despacio que el mercado de CN (13.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.7% al año) de 000739 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 000739 sea baja dentro de 3 años (17.3%).

Apeloa PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 8.1% to CN¥21.56

Price target increased by 15% to CN¥28.46

Recent updates

Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) Looks Inexpensive But Perhaps Not Attractive Enough

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.21 in 3Q 2023)

Apeloa Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 18, 2024

Investor sentiment improves as stock rises 22%

Apeloa PharmaceuticalLtd (SZSE:000739) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.31 in 2Q 2023)

Lacklustre Performance Is Driving Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Low P/E

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 16, 2024

Is Apeloa PharmaceuticalLtd (SZSE:000739) Using Too Much Debt?

Dividend increased to CN¥0.32

Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2023)

Apeloa Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 19, 2024

Price target decreased by 8.1% to CN¥21.56

Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024

Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024

New major risk - Earnings quality

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 17%

Apeloa Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 08, 2024

Investor sentiment deteriorates as stock falls 16%

Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 3Q 2022)

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2023 Results on Aug 15, 2023

Apeloa Pharmaceutical Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 22 May 2023

Price target increased by 15% to CN¥28.46

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 2Q 2021)

Investor sentiment improved over the past week

Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) announces an Equity Buyback for CNY 400 million worth of its shares.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Apeloa Pharmaceutical Co.,Ltd Proposes Final Dividend on A Shares for the Year 2021, Payable on 18 April 2022

Investor sentiment deteriorated over the past week

Apeloa Pharmaceutical Co.,Ltd Announces Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.23 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.13 in 1Q 2020)

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: EPS CN¥0.69 (vs CN¥0.47 in FY 2019)

New 90-day high: CN¥25.52

Apeloa Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day high: CN¥24.79

Third quarter earnings released

New 90-day low: CN¥22.50

Apeloa Pharmaceutical Co.,Ltd to Report Q3, 2020 Results on Oct 22, 2020

New 90-day high - CN¥27.14

Earnings released

New 90-day high - CN¥25.93

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 18, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento